21 June 2022
Visiongain has published a new report entitled Liposomal Drug Delivery Devices Market Report 2022-2032: Forecasts by Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B), by Technology (Stealth Liposome Technology, NonPEGylated Liposome Technology, DepoFoam Liposome Technology), by Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy), by End-user (Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
The global liposomal drug delivery devices market was valued at US$3,742.1 million in 2021. The global market is expected to witness a CAGR of 10.04% from 2022 to 2027 and is expected to reach US$6,600.1 million in 2027 from its previous value of US$4,091.1 million in 2022. Visiongain further anticipates that the region will reach US$11,292.6 million in 2032 while growing at a CAGR of 10.69% from 2022 to 2032.
Liposomes are paving their way into modern medicine as new applications arise. One of the applications is the topical formulation of liposomes for the treatment of skin-related infections. As technology advances, liposomal nanotechnology will become a more reliable platform for the manufacturing of a wide range of bio products, notably in the sectors of public health and medical diagnostics. As a result, industry participants in the liposomal drug delivery devices market are expected to benefit from lucrative growth prospects throughout the forecast period.
How has COVID-19 had a significant negative impact on the Liposomal Drug Delivery Devices Market?
Liposome drug delivery companies are stepping up their R&D efforts to create new lipid compositions and strategies that improve liposome stability and drug vehiculation. As a result, innovative liposomal structures have shown to be beneficial for improved therapeutic action in both vivo and vitro. Liposomes have received a lot of attention as potential antiviral drugs that could help with the social and economic effects of the COVID-19 pandemic.
How will this Report Benefit you?
Visiongain’s 535-page report provides 337 tables and 323 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global liposomal drug delivery devices market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Liposomal Drug Delivery Devices. Get financial analysis of the overall market and different segments including type, technology, application, and end-user, and capture a higher market share. We believe that there are strong opportunities in this fast-growing liposomal drug delivery devices market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximize the productivity of the company.
What are the Current Market Drivers?
Adoption of Nanomedicines to Boost Market Growth
Nanomedicine is a fast-expanding field that uses nanoscale materials to diagnose & cure diseases. Nanomedicines address the shortcomings of traditional therapy which is exhibited by several preclinical & clinical studies that show reduced side effects improved treatment results, and site-specific drug delivery. The combination of nanoscience and pharmaceutical science has a lot of promise, and it has gotten a lot of attention in recent years. Organic, inorganic, metallic & polymeric nanostructures such as micelles, dendrimers, carbon nanotubes, liposomes, & solid lipid nanoparticles (SLNs) are commonly used as controlled drug delivery techniques. Due to their tiny size, biocompatibility, and chemical composition, liposomes are regarded as one of the most promising drug delivery vehicles. Liposome qualities are highly dependent on lipid content, size, surface charge, and production methods. Liposomes can encapsulate both hydrophilic and hydrophobic medicinal medications, keeping them from dissolving too quickly and allowing them to be released at particular locations. These factors will raise the market for liposomal drug delivery devices throughout the projected period, as the need for nanomedicine will rise in the near future.
Technological Advancements in Liposomal-based Medicinal Formulations to Spur Market Demand
As a consequence of significant developments in liposome technology, a range of liposome-based pharmaceutical formulations are now accessible for human use, and many more are undergoing various clinical studies. Encapsulating several drugs in liposomes has increased its therapeutic indices, mostly through alterations in their pharmacodynamics & pharmacokinetics. Various liposomal drug delivery methods have developed distinct features in an attempt to maximise drug delivery by preserving the therapeutic agent's specific capabilities while reducing its disadvantages.
Where are the Market Opportunities?
Emergence of COVID-19 Anticipated to offer Lucrative Growth Opportunities
The COVID-19 has exposed the vulnerabilities of healthcare facilities. So far, over six million individuals have died (as of June 2022) due to the pandemic. The expanding number of COVID-19 patients, notably in the U.S. and Europe, is putting pressure on research institutes to accelerate their efforts to develop coronavirus treatments and vaccines. As a result, companies working in the liposome drug delivery industry are taking advantage of the chance to expand their research into antiviral nanomaterials such nanospheres, liposomes, and nanoparticles.
Rising Prevalence of Chronic Diseases to offer Lucrative Growth Prospects
Due to the rising frequency of chronic illness, R&D activity in liposomal drug delivery systems have exploded during the last few decades all over the world. The procedure of giving a pharmaceutical ingredient to people in order to create a therapeutic effect is known as drug delivery. Liposomal drug delivery has a number of advantages, including better pharmacokinetics and pharmacodynamics, increased therapeutic effectiveness, and lower toxicity, making it excellent for patients with a variety of chronic illnesses. According to the Centres for Condition Control and Prevention (CDC), about 6 out of 10 persons in the United States have at least one chronic disease, with 4 out of 10 having two or more. This trend is projected to grow over the forecast period thus boosting liposomal drug delivery devices industry growth.
Major players across the globe are pursuing strategic efforts such as alliances and product launches, which is expected to become a prominent trend in the market for liposomal drug delivery devices. Several firms are collaborating to develop liposomal drug delivery technologies in order to broaden their product line and extend their operations globally. For instance, in 2021, MindMed (Israel) signed a MoU (Memorandum of Understanding) to launch an exclusive program to optimize the supply of specific psychedelic drug candidates, based on Nextage's proprietary brain targeting liposome system (BTLS) supply technology.
The major players operating in the liposomal drug delivery devices market are Acrotech Biopharma, Inc., Astellas Pharma, Inc., Avanti Polar Lipids, Inc., Celsion, Inc., Creative Biolabs, Encapsula NanoSciences LLC, Fudan-Zhangjiang, Galen Limited, Ipsen Pharma, Luye Pharma Group, Merrimack Pharmaceuticals, Inc., Novartis AG, Pacira, Precision NanoSystems Inc., Viatris Inc., and Takeda Pharmaceutical Company Limited among others. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launches.
• On 15th Oct 2021, Evonik released a new version of their LIPEX® liposome extruders. LIPEX® Flow provides a better technology for bringing liposomal medicinal products to market to drug inventors and manufacturers. The innovative device fills a market demand for more efficient next-generation high-pressure extruders for manufacturing medical formulations that need traditional liposomal drug delivery. Active compounds used in cancer, antifungal, antibacterial, vaccination, and many more applications are among them.
• On 22nd March 2021, Pacira BioSciences, Inc., the U.S. Food and Drug Administration (FDA) approved the submission of its supplemental new drug application (sNDA) seeking to expand the EXPAREL label to include use in paediatric patients for single-dose infiltration to produce postsurgical local analgesia.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.